Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Dare Bioscience (DARE) over the last 4 years, with Q3 2025 value amounting to 157201.86%.

  • Dare Bioscience's EBITDA Margin fell 1459774500.0% to 157201.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 30627.16%, marking a year-over-year increase of 308157400.0%. This contributed to the annual value of 42125.02% for FY2024, which is 410505100.0% down from last year.
  • Latest data reveals that Dare Bioscience reported EBITDA Margin of 157201.86% as of Q3 2025, which was down 1459774500.0% from 18909.83% recorded in Q2 2025.
  • Dare Bioscience's EBITDA Margin's 5-year high stood at 57604.15% during Q2 2024, with a 5-year trough of 157201.86% in Q3 2025.
  • Its 4-year average for EBITDA Margin is 17447.39%, with a median of 553.96% in 2023.
  • The largest annual percentage gain for Dare Bioscience's EBITDA Margin in the last 5 years was 558766800bps (2025), contrasted with its biggest fall of -1459774500bps (2025).
  • Quarter analysis of 4 years shows Dare Bioscience's EBITDA Margin stood at 2.78% in 2022, then plummeted by -10042bps to 276.51% in 2023, then surged by 3266bps to 8755.45% in 2024, then plummeted by -1895bps to 157201.86% in 2025.
  • Its EBITDA Margin was 157201.86% in Q3 2025, compared to 18909.83% in Q2 2025 and 17167.64% in Q1 2025.